Detalhe da pesquisa
1.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer
; 154(6): 1043-1056, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994647
2.
Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
J Hepatol
; 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38570034
3.
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 401(10391): 1853-1865, 2023 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37075781
4.
Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
Hepatology
; 77(5): 1540-1549, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37070950
5.
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
Hepatology
; 78(3): 758-770, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36999533
6.
Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma.
Pancreatology
; 24(3): 424-430, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38395676
7.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int
; 44(5): 1108-1125, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38517286
8.
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors.
Future Oncol
; 2024 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38214149
9.
A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours.
Br J Cancer
; 129(2): 275-282, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37179439
10.
Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma.
Cancer Immunol Immunother
; 72(2): 371-384, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35902399
11.
FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review.
Ann Surg Oncol
; 30(7): 4417-4428, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37020094
12.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology
; 101(5): 283-291, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36657420
13.
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.
Mol Ther
; 30(8): 2800-2816, 2022 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35526096
14.
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
J Hepatol
; 77(3): 683-694, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35430299
15.
Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment.
Clin Gastroenterol Hepatol
; 20(4): 898-907, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34182151
16.
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma.
Liver Int
; 42(3): 674-681, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34792284
17.
Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib.
Future Oncol
; 18(27): 3021-3030, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35903991
18.
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Lancet Oncol
; 22(11): 1560-1572, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656226
19.
Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival.
Br J Surg
; 109(1): 61-70, 2021 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34378010
20.
Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma.
Liver Int
; 41(9): 2189-2199, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33966338